

Altus Pharmaceuticals Inc.  
Form 8-K  
February 28, 2008

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  
FORM 8-K  
CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): February 25, 2008**

**ALTUS PHARMACEUTICALS INC.**

(Exact name of registrant as specified in its charter)

**Delaware**

(State or other jurisdiction of  
incorporation)

**0-51711**

(Commission File Number)

**04-3573277**

(I.R.S. Employer Identification  
No.)

**640 Memorial Drive, Cambridge,  
Massachusetts**

(Address of principal executive  
offices)

**02139**

(Zip Code)

Registrant's telephone number, including area code: **(617) 299-2900**

Not Applicable

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**TABLE OF CONTENTS**

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;  
Compensatory Arrangements of Certain Officers.  
SIGNATURES

---

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

(a), (b), (c), (d), and (f). Not applicable.

(e) On February 25, 2008, the Compensation Committee of the Board of Directors (the Compensation Committee) of Altus Pharmaceuticals Inc. (the Company), took the following actions relating to the compensation of the individuals who were identified as named executive officers, as defined in Item 402(a)(3) of Regulation S-K, in the Company's proxy statement for its annual meeting of stockholders held in 2007 (other than Sheldon Berkle, who resigned from the Company on February 4, 2008, and whose bonus for the fiscal year ended December 31, 2007 was previously disclosed in the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on February 7, 2008) (collectively, the Named Executive Officers).

**Named Executive Officers Annual Base Salaries and Bonus Awards**

On February 25, 2008, the Compensation Committee approved the following base salaries, effective January 1, 2008, and annual cash bonus awards for performance during the fiscal year ended December 31, 2007, for the Named Executive Officers:

Named Executive Officer	2008 Annual Base Salary	2007 Bonus Award
Jonathan I. Lieber Vice President, Chief Financial Officer and Treasurer	\$284,610	\$ 71,656
Alexey L. Margolin, Ph.D.* Senior Vice President, Research and Pre-clinical Development, Chief Scientific Officer	N/A	\$ 98,223
Burkhard Blank, M.D. Executive Vice President, Chief Medical Officer	\$413,763	\$120,475
Lauren M. Sabella Vice President, Commercial Development	\$284,833	\$ 73,091

\* Dr. Margolin  
retired from the  
Company  
effective  
December 31,  
2007.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ALTUS PHARMACEUTICALS INC.**

By: /s/ Jonathan I. Lieber  
Jonathan I. Lieber  
Vice President, Chief Financial Officer  
and Treasurer

Date: February 27, 2008